What is LOPJLB’s current signal on CUE?

LOPJLB’s latest quantitative signal on Cue Biopharma, Inc. (CUE) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is CUE in?

Cue Biopharma, Inc. (CUE) is currently classified in the CRISIS HMM market regime on LOPJLB.

Cue Biopharma, Inc. (CUE)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$18.60-4.96%Close

SELLCRISIS · day 18

RANGE

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONECOIL

Key stats

Short interest · FINRA settlement 2026-09-30

Market cap: $49M
Beta: 2.63
P/E (TTM): -0.69

Short % float: 26.93%
Days to cover: 1.1
SI change: +111.4%

1W: -17.37%
1M: -41.21%

vs SPY 1W: -16.39%
vs SPY 1M: -43.08%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious…

Employees: 29
Headquarters: US
Founded: 2018
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 2.6M
Float: 99.2%

cuebiopharma.com ↗

Key executives

Lucinda Warren — Principal Fin & Accounting Off. and Chief Financial & Business Officer

Colin G. Sandercock — Senior Vice President of Intellectual Property

Shao-Lee Lin — President, CEO & Director

SEC filings

EDGAR · CIK 16454600 · CUE

Analyst consensus

Buy

Bullish9100.0%

Neutral00.0%

Bearish00.0%

L $83.00Avg $83.00H $83.00

Target$83.00+346.24%

Last$18.60

FAQ

What is LOPJLB’s current signal on CUE?: LOPJLB’s latest quantitative signal on Cue Biopharma, Inc. (CUE) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is CUE in?: Cue Biopharma, Inc. (CUE) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does Cue Biopharma, Inc. (CUE) do?: Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion pr…

Key stats

Prediction markets

Company news

FAQ